TABLE 1.
Baseline characteristics by genotypic resistance profile
| Characteristic | Value for groupa |
P valueb | ||
|---|---|---|---|---|
| LAM/ETV-R (n = 45) | LAM/ADV-R (n = 28) | LAM/ETV/ADV-R (n = 20) | ||
| Age (yr)c | 56 (32–71) | 50.5 (23–68) | 54 (29–67) | 0.499 |
| Male gender | 31 (68.9) | 22 (78.6) | 14 (70.0) | 0.652 |
| Serum HBV DNA (log10 IU/ml)c | 3.66 (0.87–7.37) | 2.95 (1.88–6.71) | 2.60 (2.02–8.23) | 0.116 |
| Serum ALT (IU/liter)c | 30 (9–275) | 27.5 (11–843) | 26.5 (14–57) | 0.636 |
| Serum creatinine (mg/dl)c | 0.86 (0.53–1.26) | 0.88 (0.53–1.31) | 0.86 (0.54–1.14) | 0.869 |
| HBeAg positive | 31 (68.9) | 18 (64.3) | 14 (70.0) | 0.893 |
| Liver cirrhosisd | 16 (35.6) | 8 (28.6) | 4 (20.0) | 0.469 |
| Lines of prior antiviral treatment | 2 (1–5) | 3 (2–5) | 5 (3–5) | <0.001 |
| Duration of previous treatment (mo)c | 28.2 (2.7–78.7) | 17.5 (2.7–85.7) | 17.5 (1.4–40.2) | 0.028 |
| Time point of rescue therapy | ||||
| Virologic breakthrough | 21 (46.7) | 11 (39.3) | 5 (25.0) | 0.257 |
| Biochemical breakthrough | 17 (37.8) | 6 (21.4) | 6 (30.0) | 0.339 |
a
Unless otherwise indicated, data are number of patients, with percentages in parentheses. LAM, lamivudine; ETV, entecavir; ADV, adefovir; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen.
b
The Kruskal-Wallis test and χ2 test (or Fisher's exact test) were used to analyze the differences among the groups.
c
Data are medians, with ranges in parentheses.
d
Liver cirrhosis was diagnosed when the platelet count was below 100,000/mm3 and associated splenomegaly or esophageal-gastric varices were detected.